Fixed drug eruption with interferon-β-1b

Australasian Journal of Dermatology

Volumn 46, Issue 3, 2005, Pages 154-157

  Tai, Yee J ^a,b   Tam, Mei ^a  

^a ST VINCENT S HOSPITAL   (Australia)

^b NONE   (Australia)

Author keywords

Cutaneous reaction; Multiple sclerosis; Trunk

Indexed keywords

DEXAMETHASONE; GLATIRAMAR ACETATE; IMMUNOMODULATING AGENT; INTERFERON BETA SERINE; METHYLPREDNISOLONE; OMEPRAZOLE; PARACETAMOL; RAMIPRIL; ROFECOXIB; UNCLASSIFIED DRUG;

ABDOMEN; ADULT; ANAMNESIS; ARTICLE; CASE REPORT; CONGESTIVE HEART FAILURE; DRUG ERUPTION; DRUG TOLERABILITY; ERYTHEMA; FEMALE; HISTOPATHOLOGY; HUMAN; INJECTION SITE REACTION; MULTIPLE SCLEROSIS; PAPULE; PUNCH BIOPSY; REFLUX ESOPHAGITIS; THIGH; VIRUS MYOCARDITIS;

ADJUVANTS, IMMUNOLOGIC; ADULT; DRUG ERUPTIONS; FEMALE; HUMANS; INJECTIONS, SUBCUTANEOUS; INTERFERON-BETA; MULTIPLE SCLEROSIS;

EID: 23844477226     PISSN: 00048380     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-0960.2005.00168.x     Document Type: Article

References (19)

1. The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1995; 45: 655-61.
2. European Study Group on interferon beta-1b in secondary progressive MS. Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. Lancet 1998; 552: 1491-7.
3. Elgart GW, Sheremata W, Ahn YS. Cutaneous reactions to recombinant human interferon beta-1b: the clinical and histologic spectrum. J. Am. Acad. Dermatol. 1997; 57: 555-8.
4. Runkel L, Meier W, Pepinsky RB, Karpusas M, Whitty A, Kimball K, Brickelmaier M, Muldowney C, Jones W, Goelz SE. Structural and functional differences between glycosylated and nonglycosylated forms of human interferon-beta. Pharm. Res. 1998; 15: 641-9.
5. Yong VW, Chabot S, Stuve O, Williams G. Interferon beta in the treatment of multiple sclerosis. Mechanisms of action. Neurology 1998; 51: 682-9.
6. Walther EU, Hohlfeld R. Multiple sclerosis. Side effects of interferon beta therapy and their management. Neurology 1999; 55: 1622-8.
7. Dereure O, Raison-Peyron N, Larrey D, Blanc F, Guilhou JJ. Diffuse inflammatory lesions in patients treated with interferon alfa and ribavirin for hepatitis C: a series of 20 patients. Br. J. Dermatol. 2002; 147: 1142-6.
8. Sookoian S, Neglia V, Castano G, Frider B, Kien MC, Chohuela E. High prevalence of cutaneous reactions to interferon alfa plus ribavirin combination therapy in patients with chronic hepatitis C virus. Arch. Dermatol. 1999; 135: 1000-1.
9. Sidhu-Malik NK, Kaplan AL. Multiple fixed drug eruption with interferon/ribavirin combination therapy for hepatitis C virus infection. J. Drugs Dermatol. 2003; 2: 570-3.
10. Stubb S. Blood leukocytes, with special reference to basophils and eosinophils, during provocation tests in fixed drug eruption and drug exanthema. Acta Derm. Venereol. Suppl. 1976; 56: 1-47.
11. Sehgal VN, Gangwani OP. Fixed drug eruption. Current concepts. Int. J. Dermatol. 1987; 26: 67-74.
12. Stritzler C, Ropf AW. Fixed drug eruption caused by 8-chlorotheophylline in dramamine with clinical and histologic studies. J. Invest. Dermatol. 1960; 54: 319-50.
13. Alanko K, Stubb S, Reitamo S. Topical provocation of fixed drug eruption. Br. J. Dermatol. 1987; 116: 561-7.
14. Ozkaya-Bayazit E, Bayazit H, Ozarmagan G. Topical provocation in 27 cases of cotrimoxazole-induced fixed drug eruption. Contact Dermatitis 1999; 41: 185-9.
15. Korkij W, Soltani R. Fixed drug eruption. A brief review. Arch. Dermatol. 1984; 120: 520-4.
16. Teraki Y, Moriya N, Shiohara T. Drug-induced expression of intercellular adhesion molecule-1 on lesional keratinocytes in fixed drug eruption. Am. J. Path. 1994; 145: 550-60.
17. Shiohara T, Mizukawa Y, Teraki Y. Pathophysiology of fixed drug eruption: the role of skin-resident T cells. Curr. Opin. Allergy Clin. Immunol. 2002; 2: 317-23.
18. Mizukawa Y, Yamazaki Y, Teraki Y, Hayakawa J, Hayakawa K, Nuriya H, Rohara M, Shiohara T. Direct evidence for interferon-gamma production by effector-memory-type intraepidermal T cells residing at an effector site of immunopathology in fixed drug eruption. Am. J. Path. 2002; 161: 1337-47.
19. Pellicano R, Civarella G, Lomuto M, Di-Giorgio G. Genetic susceptibility to fixed drug eruption. Evidence of link with HLA-B22. J. Am. Acad. Dermatol. 1994; 30: 52-4.